Lista de obras - Eugeen Vanmechelen - Dominio Público Uruguay

1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France

article

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

artículo científico publicado en 2016

A Practical Guide to Immunoassay Method Validation

artículo científico publicado en 2015

A new era of CSF biomarker testing in the field of Alzheimer's disease

scholarly article by Sebastiaan Engelborghs et al published July 2013 in Alzheimer's and Dementia

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele

artículo científico publicado en 1995

Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion.

artículo científico publicado en 1999

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders

artículo científico publicado en 2012

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

artículo científico publicado en 2009

Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection

artículo científico publicado en 1992

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

artículo científico publicado en 2005

Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

artículo científico publicado en 2009

Analytical aspects of molecular Alzheimer's disease biomarkers

artículo científico publicado en 2012

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

artículo científico publicado en 2006

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

article

Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease

artículo científico publicado en 2002

Association of brain network dynamics with plasma biomarkers in subjective memory complainers

artículo científico publicado en 2019

Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies.

artículo científico publicado en 2006

Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

artículo científico publicado en 2008

Both total and phosphorylated tau are increased in Alzheimer's disease

artículo científico publicado en 2001

Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD

scientific article published on 01 October 2019

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

artículo científico publicado en 2015

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

artículo científico publicado en 2000

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry

artículo científico publicado en 2003

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

artículo científico publicado en 2001

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

artículo científico publicado en 2000

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

artículo científico publicado en 2008

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

artículo científico publicado en 2003

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease

artículo científico publicado en 1999

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

scientific article published on 01 January 2003

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

artículo científico publicado en 2000

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease

scholarly article by Bjørn-Eivind Kirsebom et al published 2018 in Alzheimer's & dementia (New York, N. Y.)

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

scientific article published on 01 September 1999

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

artículo científico publicado en 2001

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

artículo científico publicado en 1998

Characterization of tau in cerebrospinal fluid using mass spectrometry

artículo científico publicado en 2008

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

artículo científico publicado en 1998

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia

artículo científico publicado en 2013

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

scientific article published on 12 December 2019

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms

artículo científico publicado en 2002

Detection and quantification of novel tau/phospho-tau epitopes in CSF using a multiplex assay approach

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay

artículo científico publicado en 1993

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

artículo científico publicado en 2010

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

artículo científico publicado en 2007

Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples

artículo científico publicado en 2018

Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein

artículo científico publicado en 1994

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

scholarly article by Joakim Hertze et al published 10 September 2010 in Journal of Alzheimer's Disease

Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years

artículo científico publicado en 2010

Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease

artículo científico publicado en 2001

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

artículo científico publicado en 2001

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

artículo científico publicado en 2008

Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study

artículo científico publicado en 2012

Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype

artículo científico publicado en 1999

Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment

artículo científico publicado en 2009

Expression of a paired helical filament tau epitope in embryonic chicken central nervous system ⬇️

artículo científico publicado el 9 de mayo de 1994

Functional mannose-binding lectin haplotype variants are associated with Alzheimer's disease

artículo científico publicado en 2013

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.

artículo científico publicado en 2003

Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis

artículo científico publicado en 2006

Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method

artículo científico publicado en 2011

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

artículo científico publicado en 1999

Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels

artículo científico publicado en 2014

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

artículo científico publicado en 2007

Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment

artículo científico publicado en 2001

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

artículo científico publicado en 2004

Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation

scientific article published on 01 December 1996

Monitoring of β-amyloid dynamics after human traumatic brain injury

artículo científico publicado en 2013

Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205.

artículo científico publicado en 1995

Multicenter Analytical Validation of Aβ40 Immunoassays.

artículo científico publicado en 2017

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study

artículo científico publicado en 2007

Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study

scholarly article published in Dementia and geriatric cognitive disorders extra

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke

artículo científico publicado en 2017

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study

artículo científico publicado en 2018

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

artículo científico publicado en 2010

Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia

artículo científico publicado en 2004

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

artículo científico publicado en 2007

Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease

artículo científico publicado en 2000

P3-071: Mass spectrometric characterization of tau in cerebrospinal fluid

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

artículo científico publicado en 2003

Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease

artículo científico publicado en 2002

Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study

artículo científico publicado en 2005

Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism

artículo científico publicado en 2005

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

artículo científico publicado en 2019

Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins

artículo científico publicado en 2004

Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia

artículo científico publicado en 2011

Potential sources of interference on Abeta immunoassays in biological samples

artículo científico publicado en 2012

Pre-analytical stability of novel cerebrospinal fluid biomarkers

artículo científico publicado en 2019

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

artículo científico publicado en 2000

Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update

artículo científico publicado en 2012

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

artículo científico publicado en 2018

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample

artículo científico publicado en 1999

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology

artículo científico publicado en 2004

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma

artículo científico publicado en 2000

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers

artículo científico publicado en 2005

TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES

article

TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies

artículo científico publicado en 2015

Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

artículo científico publicado en 2001

Tau as a biomarker of neurodegenerative diseases.

artículo científico publicado en 2008

Tau as a molecular biomarker in cerebrospinal fluid and plasma

article published in 2014

Tau immunoreactivity detected in human plasma, but no obvious increase in dementia

artículo científico publicado en 1999

Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics

artículo científico publicado en 2014

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

artículo científico publicado en 1995

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease

artículo científico publicado en 2016

The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease

artículo científico publicado en 1999

The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process

scholarly article by M Sjögren et al published 1 July 2001 in Dementia and Geriatric Cognitive Disorders

The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease

artículo científico publicado en 2005

The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?

scientific article published on 01 March 2019

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

artículo científico

The β-Secretase BACE1 in Alzheimer's Disease

artículo científico publicado en 2020

Towards an earlier diagnosis of Alzheimer's disease.

artículo científico publicado en 1998

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

artículo científico publicado en 2001

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

artículo científico publicado en 2003

Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets

artículo científico publicado en 2003

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

artículo científico publicado en 2015

Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases

artículo científico publicado en 2016

β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification

artículo científico publicado en 2020

Lista de obras de Eugeen Vanmechelen

1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

A Practical Guide to Immunoassay Method Validation

A new era of CSF biomarker testing in the field of Alzheimer's disease

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele

Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased Abeta42 secretion.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing

Analytical aspects of molecular Alzheimer's disease biomarkers

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease

Association of brain network dynamics with plasma biomarkers in subjective memory complainers

Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies.

Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

Both total and phosphorylated tau are increased in Alzheimer's disease

Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

Characterization of tau in cerebrospinal fluid using mass spectrometry

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia

Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms

Detection and quantification of novel tau/phospho-tau epitopes in CSF using a multiplex assay approach

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein Tau in biological samples

Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years

Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study

Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype

Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment

Expression of a paired helical filament tau epitope in embryonic chicken central nervous system ⬇️

Functional mannose-binding lectin haplotype variants are associated with Alzheimer's disease

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.

Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis

Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation

Monitoring of β-amyloid dynamics after human traumatic brain injury

Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205.

Multicenter Analytical Validation of Aβ40 Immunoassays.

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study

Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease

Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease

P3-071: Mass spectrometric characterization of tau in cerebrospinal fluid

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease

Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study